secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001193125-22-064358
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track
----------------------------------------------------------------------

- Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.
- Cash and cash equivalents $302.2M at year-end 2021; no revenue reported.
- IND for TYRA-300 (FGFR3) expected mid-2022; TYRA-200 (FGFR2) in H2 2022.
- Appointed Allison Kemner as VP Clinical Sciences and Operations in Q4 2021.
- Added to Russell 2000 Index in December 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/0001193125-22-064358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/d265803d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-064358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer